Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Leap Therapeutics’ dense antibody trial data, equity offerings, and risk factors can feel like decoding a lab notebook. Clinical-stage oncology companies publish highly technical disclosures, and the latest 10-Q already runs 200+ pages. If you have ever typed “Leap Therapeutics insider trading Form 4 transactions” or “Leap Therapeutics quarterly earnings report 10-Q filing” into Google, you know the challenge: the information is there, but buried.
Stock Titan solves this problem instantly. Our AI reads each document as soon as it hits EDGAR and delivers plain-English summaries for every form—from a sudden 8-K describing trial setbacks to the detailed 10-K. That means Leap Therapeutics Form 4 insider transactions real-time alerts on your screen within minutes, side-by-side with clear charts. Prefer guidance instead of jargon? You’ll find Leap Therapeutics SEC filings explained simply, a dedicated section that links cash-runway tables to pipeline timelines and provides Leap Therapeutics earnings report filing analysis you can act on.
Here’s how professionals use the page:
- Track Leap Therapeutics executive stock transactions Form 4 before financing announcements.
- Download the Leap Therapeutics annual report 10-K simplified to see R&D spend vs. milestone receipts.
- Scan the Leap Therapeutics proxy statement executive compensation for incentive alignment.
- Get Leap Therapeutics 8-K material events explained to monitor trial halts or new partnerships.
Whether you are understanding Leap Therapeutics SEC documents with AI for the first time or building a detailed valuation model, Stock Titan delivers real-time updates, AI-powered summaries and expert context—so you focus on decisions, not page counts.
Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.
Cypherpunk Technologies Inc. (CYPH)11/11/2025, Director and officer Douglas E. Onsi received 2,087,287 restricted stock units (RSUs) under the company’s 2016 Equity Incentive Plan for $0 consideration.
The RSUs vest as follows: 12/36th on October 8, 2026 and 1/36th on the 8th day of each month thereafter, subject to continued service. Vested RSUs will be settled in common stock at the earliest of: the first payroll period after the end of the reporting person’s employment or service, the first payroll period on or after the 8th day of June following any applicable Vesting Date, or the first payroll period on or after the 8th day of December following any applicable Vesting Date.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) under the Company’s 2022 Equity Incentive Plan for no consideration, each RSU deliverable into one share of common stock.
The RSUs vested at issuance on the grant date. Settlement into common shares will occur as soon as practicable after the earlier of the fifth business day following the director’s service ending or the first annual meeting of stockholders following the grant date.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. A Form 4 discloses an award of 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, par value $0.001, and the award was granted for no consideration.
The RSUs vested at issuance on the grant date and will be settled in common stock as soon as practicable after the earlier of (i) the fifth business day following the director’s departure from the Board or (ii) the first annual meeting of stockholders following the grant date. Following the reported transaction, the director holds 74,700 derivative securities on a direct ownership basis.
Cypherpunk Technologies (CYPH)November 11, 2025, the director received 74,700 restricted stock units (RSUs) for no cash consideration under the 2022 Equity Incentive Plan. The RSUs vested at issuance.
Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual stockholder meeting after the grant date.
Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant. A director received 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration, with each RSU settling 1-for-1 into common stock.
The RSUs vested at issuance. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the board or the first annual meeting of stockholders following the grant date. Following the transaction, the filing lists 74,700 derivative securities held direct.
Cypherpunk Technologies Inc. (CYPH) filed a Form 4 reporting an equity grant to a director. On November 11, 2025, the reporting person was awarded 74,700 restricted stock units (RSUs) priced at $0 under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date, with settlement in common stock on a one-for-one basis. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual meeting of stockholders after the grant date, subject to applicable tax withholdings.
Cypherpunk Technologies Inc. (CYPH) reported a director equity award on Form 4. The reporting person received 74,700 restricted stock units (RSUs) on November 11, 2025 at an exercise price of $0, granted under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock on the earlier of the fifth business day after the reporting person ceases to serve on the board or the first annual meeting of stockholders following the grant date. Following the transaction, the reporting person holds 74,700 derivative securities directly.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant on a Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) awarded for $0 under the company’s 2016 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock after the earlier of the fifth business day following the director’s service end or the first annual stockholders’ meeting after the grant. Following the transaction, the reporting person beneficially owned 74,700 derivative securities, held directly.
Cypherpunk Technologies Inc. (CYPH) reported a director’s equity grant on a Form 4. The director received 83,000 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration.
The RSUs vested at issuance on the grant date. Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s service end or the first annual stockholder meeting following the grant date. The RSUs are shown as direct (D) ownership.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
